1. Bray, F., et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018. 68(6): p. 394-424.
2. Dela Cruz, C.S., L.T. Tanoue, and R.A. Matthay, Lung cancer: epidemiology, etiology, and prevention. Clinics in chest medicine, 2011. 32(4): p. 605-644.
3. Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2019. CA Cancer J Clin, 2019. 69(1): p. 7-34.
4. Warburg, O., On the origin of cancer cells. Science, 1956. 123(3191): p. 309-14.
5. Boedtkjer, E. and S.F. Pedersen, The Acidic Tumor Microenvironment as a Driver of Cancer. Annu Rev Physiol, 2020. 82: p. 103-126.
6. Chiche, J., M.C. Brahimi-Horn, and J. Pouyssegur, Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer. J Cell Mol Med, 2010. 14(4): p. 771-94.
7. Wang, G.L., et al., Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proceedings of the National Academy of Sciences of the United States of America, 1995. 92(12): p. 5510-5514.
8. Pugh, C.W. and P.J. Ratcliffe, Regulation of angiogenesis by hypoxia: role of the HIF system. Nature Medicine, 2003. 9(6): p. 677-684.
9. Fujimura, A., et al., Cyclin G2 promotes hypoxia-driven local invasion of glioblastoma by orchestrating cytoskeletal dynamics. Neoplasia (New York, N.Y.), 2013. 15(11): p. 1272-1281.
10. Kierans, S.J. and C.T. Taylor, Regulation of glycolysis by the hypoxia-inducible factor (HIF): implications for cellular physiology. J Physiol, 2021. 599(1): p. 23-37.
11. Zhong, X.Y., et al., CARM1 Methylates GAPDH to Regulate Glucose Metabolism and Is Suppressed in Liver Cancer. Cell Rep, 2018. 24(12): p. 3207-3223.
12. DeWaal, D., et al., Author Correction: Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin. Nat Commun, 2018. 9(1): p. 2539.
13. Liberti, M.V., et al., A Predictive Model for Selective Targeting of the Warburg Effect through GAPDH Inhibition with a Natural Product. Cell Metab, 2017. 26(4): p. 648-659.e8.
14. Yun, J., et al., Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science, 2015. 350(6266): p. 1391-6.
15. Wolf, A., et al., Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med, 2011. 208(2): p. 313-26.
16. Wyatt, E., et al., Regulation and cytoprotective role of hexokinase III. PLoS One, 2010. 5(11): p. e13823.
17. Zhang, J.Y., et al., Critical protein GAPDH and its regulatory mechanisms in cancer cells. Cancer Biol Med, 2015. 12(1): p. 10-22.
18. Lay, A.J., et al., Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase. Nature, 2000. 408(6814): p. 869-73.
19. Ahmad, S.S., et al., Phosphoglycerate kinase 1 as a promoter of metastasis in colon cancer. Int J Oncol, 2013. 43(2): p. 586-90.
20. Carnielli, C.M., et al., Combining discovery and targeted proteomics reveals a prognostic signature in oral cancer. Nat Commun, 2018. 9(1): p. 3598.
21. Townsend, M.H., et al., Potential new biomarkers for endometrial cancer. Cancer Cell Int, 2019. 19: p. 19.
22. Fu, D., et al., PGK1 is a Potential Survival Biomarker and Invasion Promoter by Regulating the HIF-1α-Mediated Epithelial-Mesenchymal Transition Process in Breast Cancer. Cell Physiol Biochem, 2018. 51(5): p. 2434-2444.
23. Zhang, Y., et al., Activation of PGK1 under hypoxic conditions promotes glycolysis and increases stem cell‑like properties and the epithelial‑mesenchymal transition in oral squamous cell carcinoma cells via the AKT signalling pathway. Int J Oncol, 2020. 57(3): p. 743-755.
24. Zhang, W. and H.T. Liu, MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res, 2002. 12(1): p. 9-18.
25. Robey, I.F., et al., Hypoxia-inducible factor-1alpha and the glycolytic phenotype in tumors. Neoplasia (New York, N.Y.), 2005. 7(4): p. 324-330.
26. Maxwell, P.H., et al., Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci U S A, 1997. 94(15): p. 8104-9.
27. Hay, N., Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy? Nature Reviews Cancer, 2016. 16(10): p. 635-649.
28. Patra, K.C., et al., Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell, 2013. 24(2): p. 213-228.
29. Minchenko, O.H., et al., 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene family overexpression in human lung tumor. Ukr Biokhim Zh (1999), 2005. 77(6): p. 46-50.
30. Xie, H., et al., Targeting lactate dehydrogenase--a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells. Cell Metab, 2014. 19(5): p. 795-809.
31. Cheng, J.Q., et al., Transforming activity and mitosis-related expression of the AKT2 oncogene: evidence suggesting a link between cell cycle regulation and oncogenesis. Oncogene, 1997. 14(23): p. 2793-801.
32. Mahajan, K. and N.P. Mahajan, PI3K-independent AKT activation in cancers: a treasure trove for novel therapeutics. Journal of cellular physiology, 2012. 227(9): p. 3178-3184.
33. Staal, S.P., Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proceedings of the National Academy of Sciences, 1987. 84(14): p. 5034-5037.
34. Bellacosa, A., et al., Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. International journal of cancer, 1995. 64(4): p. 280-285.
35. Cheng, J.Q., et al., Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proceedings of the National Academy of Sciences, 1996. 93(8): p. 3636-3641.
36. Elstrom, R.L., et al., Akt stimulates aerobic glycolysis in cancer cells. Cancer Res, 2004. 64(11): p. 3892-9.
37. Hajduch, E., G.J. Litherland, and H.S. Hundal, Protein kinase B (PKB/Akt) – a key regulator of glucose transport? FEBS Letters, 2001. 492(3): p. 199-203.
38. Guo, Y.J., et al., ERK/MAPK signalling pathway and tumorigenesis. Exp Ther Med, 2020. 19(3): p. 1997-2007.
39. Pouysségur, J., F. Dayan, and N.M. Mazure, Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature, 2006. 441(7092): p. 437-43.
40. Semenza, G.L. and G.L. Wang, A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol, 1992. 12(12): p. 5447-54.
41. Muz, B., et al., The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckland, N.Z.), 2015. 3: p. 83-92.
42. Giatromanolaki, A., et al., Relation of hypoxia inducible factor 1 α and 2 α in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. British journal of cancer, 2001. 85(6): p. 881-890.
43. Detterbeck, F.C., et al., The Eighth Edition Lung Cancer Stage Classification. Chest, 2017. 151(1): p. 193-203.